In COVID-19 clinical update #96, Daniel Griffin reviews Omicron in South Africa, rapid antigen tests, viral coinfections, isolation and quarantine, saliva preferred for Omicron, risk factors for severe disease in vaccinated, Paxlovid dosing, and long COVID.
In COVID-19 clinical update #95, Daniel Griffin discusses new CDC guidelines for isolation and quarantine, EUA for Molnupiravir, children and COVID, vaccine safety in 5-11 year olds, Omicron outbreaks in Nebraska and Denmark, Baylor’s COVID vaccine, and COVID-OUT for ivermectin.
In COVID-19 clinical update #94, Daniel Griffin reviews the FDA EUA for Paxlovid, test to stay in school, immunity after infection, variants and therapeutics, quarantine and isolation guidelines, Molnupiravir in non-hospitalized patients, and convalescent serum in outpatients.
In COVID-19 clinical update #93, Dr. Griffin summarizes Omicron fitness, S-gene target failure, monoclonal efficacy against Omicron, vaccination, monoclonals, and disease in children, persistence of memory B cells in the elderly, infection and vaccine induced immunity, protection against severe illness and death by a third mRNA vaccine dose, high flow oxygen versus intubation, and therapeutic anticoagulation.
In COVID-19 clinical update #92, Dr. Griffin reviews emerging data on the Omicron variant, much information about monoclonal antibody treatment, including expansion of EUA for Lilly’s cocktail, FDA EUA for pre-exposure prophylaxis, outcomes after treatment, and investigation of subcutaneous or intramuscular administration; effect of adding immunomodulatory agents to usual care on thromboembolic events, and long COVID following infection in previously vaccinated individuals.
In COVID-19 clinical update #91, Dr. Griffin discusses final results of molnupiravir trial, Omicron variant of concern, outcomes in B-cell depleted patients, recovery in T-cell depleted macaques, peptide for induction of T cell immunity, high respiratory viral RNA loads in infants, IgA and T cells transferred to breast milk after vaccination, sensitivity and specificity of ID NOW, post-acute sequelae at 12 months, disease in low and middle income countries.
In COVID-19 clinical update #90, Dr. Griffin covers FDA expansion for booster doses, 3 more at home antigen tests approved by FDA, immune correlates analysis of mRNA-1273 vaccine, risk for stillbirth, PROVENT prophylaxis trial results, fluvoxamine recommendations, advice on molnupiravir, automated text messaging service for monitoring illness, and long COVID-19 after vaccination and infection.
In COVID-19 clinical update #89, Dr. Griffin reviews upcoming meeting on FDA emergency use authorization for molnupiravir, 25% of US cases in children, reinfection associates with presence of antibodies, national surveillance for acute flaccid myelitis in the US, and monoclonal antibody treatment of infection in vaccinated, high-risk individuals.
In COVID-19 clinical update #88, Dr. Griffin covers vaccine protection among US veterans, absence of long COVID in vaccinated who are infected, single dose of REGEN-COV monoclonal antibody cocktail provides long term protection, and Pfizer protease inhibitor Paxlovid is 89% effective in preventing hospitalization or death.
In COVID-19 clinical update #87, Dr. Griffin reviews PCR cycle threshold and RNA copy number, rapid antigen tests, hospitalization rate after infection or vaccination, allergies and vaccination, community transmission and viral RNA load, early treatment with sotrovimab, meta-analysis of tocilizumab treatment, antibiotic overuse, and guidelines on the use of anticoagulation for thromboprophylaxis.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Dickson D.
Despommier, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Jolene Ramsey, Ph.D.